Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

Blueprint Medicines (NASDAQ: BPMC) Corporation, a commercial-stage biotechnology company with a market capitalization of $8.27 billion, has been making significant strides in the pharmaceutical ...